SB 328437
SIGMA/SML0207 - ≥98% (HPLC)
Synonym: L-Phenylalanine, N-
CAS Number: 247580-43-4
Empirical Formula (Hill Notation): C21H18N2O5
Molecular Weight: 378.38
MDL Number: MFCD16618397
Linear Formula: C21H18N2O5
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to tan |
form | powder |
InChI | 1S/C21H18N2O5/c1-28-21(25 |
InChI key | VMFGCGRAIBLAFY-IBGZPJMESA |
originator | GlaxoSmithKline |
Quality Level | 100 |
SMILES string | COC(=O)[C@H](Cc1ccc(cc1)[ |
solubility | DMSO: ≥10 mg/mL |
storage temp. | 2-8°C |
Application: | SB 328437 may be used to study CCR3-mediated cell signaling in asthma models. |
Biochem/physiol Actions: | SB 328437 inhibits the recruitment and migration of eosinophils in allergen models of models. It suppresses the Th2-mediated eosinophil infiltration in the airways. |
Biochem/physiol Actions: | SB-328437 is a potent, selective CCR-3 antagonist (IC50 = 1.6 nM). The compound blockes CCR3 agonist-induced calcium mobilization in CCR3 expressing cells with the following IC50 values: eotaxin, 38 nM; eotaxin-2, 35 nM and MCP4, 20 nM. |
Features and Benefits: | This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: | 5, 25 mg in glass bottle |
Hazard Codes | Xn,N |
Risk Statements | 22-50 |
Safety Statements | 60-61 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352200 |